MetaVia

MetaVia FCF Yield

The Free Cash Flow Yield of MetaVia (MTVA) as of Oct 30, 2026 is -288.82 %. In the previous year, Free Cash Flow Yield was -454.64 % — a change of -36.47% (higher).

FCF Yield

-288.82 %

YoY

-36.47%

Last updated:

Free Cash Flow Yield of MetaVia is 2025 -288.82 % . Free Cash Flow Yield of MetaVia was 2024 -454.64 % . It decreases by -36.47% higher compared to the previous year.

The MetaVia FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
-265.85 USD
Jan 1, 2019
-133.40 USD
Jan 1, 2020
-198.06 USD
Jan 1, 2021
-278.41 USD
Jan 1, 2022
-215.42 USD
Jan 1, 2023
-199.54 USD
Jan 1, 2024
-454.64 USD
Jan 1, 2025
-288.82 USD
The MetaVia FCF Yield history
YEARFCF YieldYoY
-288.82 %-36.47%
-454.64 %+127.84%
-199.54 %-7.37%
-215.42 %-22.63%
-278.41 %+40.57%
-198.06 %+48.46%
-133.40 %-49.82%
-265.85 %-46.27%
-494.79 %+143.60%
-203.11 %+103.26%
-99.93 %+2,686.15%
-3.59 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MetaVia Stock analysis

What does MetaVia do? NeuroBo Pharmaceuticals, Inc. generates revenue by developing novel pharmaceuticals to address unmet medical needs in patients suffering from neurodegenerative disorders. The company focuses on specific therapeutic areas including Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease, targeting these conditions with its proprietary product candidates. This strategy allows the firm to serve the clinical-stage biotechnology market by offering specialized treatments for serious health conditions. The company’s product portfolio includes NB-01, which is designed to target neuropathic pain with an indication for PDN, and NB-02, a drug developed for Alzheimer’s and tauopathies. Additionally, the firm offers Gemcabene, a therapy focused on treating dyslipidemia, a condition that increases the risk of life-threatening cardiovascular disease. Gemcabene is specifically directed at orphan indications such as homozygous familial hypercholesterolemia (HoFH) and severe hypertriglyceridemia (SHTG). Furthermore, NeuroBo Pharmaceuticals, Inc. is developing a capsule formulation of niclosamide for coronavirus indications. By expanding its research into these diverse medical conditions, the company aims to provide comprehensive pharmaceutical solutions. The firm operates from its headquarters in Boston, Massachusetts, and maintains a focused development pipeline to bring these treatments to market. MetaVia is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MetaVia stock

Free Cash Flow Yield of MetaVia is -288.82 % in 2025.

Free Cash Flow Yield of MetaVia changed from -454.64 % to -288.82 %, representing a -36.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield MetaVia since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's MetaVia with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — MetaVia

All Key Metrics — MetaVia